Italian biopharmaceutical company Dompé farmaceutici has secured approval from the US Food and Drug Administration (FDA) for the use of its Oxervate medicine to treat neurotrophic keratitis.
Oxervate is said to be the first FDA-approved drug for this rare, degenerative disease, which causes corneal scarring and vision loss.
Go deeper with GlobalData
The drug is based on a recombinant human nerve growth factor (rhNGF) called cenegermin-bkbj. This nerve growth factor is similar in structure to a natural one present in human body.
FDA Center for Drug Evaluation and Research ophthalmologist Wiley Chambers said: “In the past, it has often been necessary to turn to surgical interventions; these treatments are usually only palliative in this disease.
“Today’s approval provides a novel topical treatment and a major advance that offers complete corneal healing for many of these patients.”
Oxervate’s safety and efficacy were assessed in two randomised, controlled, multi-centre, double-masked clinical studies conducted in a total of 150 subjects over eight weeks.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe first study enrolled patients with neurotrophic keratitis in only one eye, while the second study involved subjects who were affected in both eyes. Oxervate eye drops were administered six times daily.
Patients in the first trial were treated with Oxervate, an eye drop with a different concentration of cenegermin, or an eye drop without cenegermin.
During the second study, participants were randomised to receive either Oxervate or an eye drop without cenegermin.
Data from both the trials showed that 70% of the patients treated with Oxervate achieved complete corneal healing in eight weeks, compared to 28% who were administered eye drop without cenegermin.
The most common adverse reactions associated with Oxervate were eye pain, ocular hyperaemia, eye inflammation and increased lacrimation.
